Amgen's Repatha Meets Endpoints In GAUSS-3 Trial
This article was originally published in Scrip
Executive Summary
Results from Amgen's Phase III GAUSS-3 trial evaluating Repatha (evolocumab) in patients with high cholesterol have added to the growing evidence that the novel drug has the ability to reduce LDL (low-density lipoprotein) cholesterol in those patients who cannot tolerate statins or decrease levels of this 'bad' cholesterol through diet.
You may also be interested in...
Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Adherence Issues Add Weight To Digital Trials Push
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
Appointments: Five Prime, Depomed, Gilead, Arix Bioscience and Corbus
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.